Skip to main content
رجوع
BMRN logo

BioMarin Pharmaceutical Inc.

جودة البيانات: 100%
BMRN
NASDAQ Healthcare Biotechnology
KWD 54.09
▼ KWD 0.69 (-1.26%)
القيمة السوقية: 10.40B
نطاق اليوم
KWD 53.36 KWD 54.37
نطاق 52 أسبوعًا
KWD 50.76 KWD 73.18
حجم التداول
1,648,594
متوسط 50 يوم / 200 يوم
KWD 58.63 / KWD 56.59
الإغلاق السابق
KWD 54.78

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Healthcare (627 نظير)

المقياس السهم وسيط القطاع
P/E 29.8 0.3
P/B 1.7 2.9
ROE % 5.9 3.7
Net Margin % 10.8 3.8
Rev Growth 5Y % 14.9 10.0
D/E 0.1 0.2

السعر المستهدف للمحللين

Hold
KWD 86.600 +60.1%
Low: KWD 60.000 High: KWD 105.000
مكرر الربحية المستقبلي
12.7
ربحية السهم المستقبلية
KWD 4.322
نمو ربحية السهم (تقدير)
+0.0%
الإيرادات المقدّرة
3.6 B

تقديرات الأرباح

الفترة تقدير ربحية السهم تقدير الإيرادات المحللون
FY2030 KWD 8.396
KWD 7.979 – KWD 8.823
5.1 B 6
FY2029 KWD 7.570
KWD 7.195 – KWD 7.955
4.8 B 6
FY2028 KWD 6.758
KWD 4.898 – KWD 9.013
4.4 B 8

النقاط الرئيسية

Revenue grew 14.93% annually over 5 years — strong growth
Earnings declined -18.26% over the past year
Debt/Equity of 0.11 — conservative balance sheet
Generating 724.96M in free cash flow
Cash machine — converts 207.78% of earnings into free cash flow
Capital efficient — spends only 3.20% of revenue on capex

النمو

Revenue Growth (5Y)
14.93%
Revenue (1Y)12.87%
Earnings (1Y)-18.26%
FCF Growth (3Y)240.39%

الجودة

Return on Equity
5.94%
ROIC5.95%
Net Margin10.83%
Op. Margin16.56%

الأمان

Debt / Equity
0.11
Current Ratio5.21
Interest Coverage48.95

التقييم

P/E Ratio
29.82
P/B Ratio1.71
EV/EBITDA18.25
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 12.87% Revenue Growth (3Y) 15.39%
Earnings Growth (1Y) -18.26% Earnings Growth (3Y) 44.26%
Revenue Growth (5Y) 14.93% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 3.22B Net Income (TTM) 348.90M
ROE 5.94% ROA 4.59%
Gross Margin 77.13% Operating Margin 16.56%
Net Margin 10.83% Free Cash Flow (TTM) 724.96M
ROIC 5.95% FCF Growth (3Y) 240.39%
Safety
Debt / Equity 0.11 Current Ratio 5.21
Interest Coverage 48.95 Dividend Yield 0.00%
Valuation
P/E Ratio 29.82 P/B Ratio 1.71
P/S Ratio 3.23 PEG Ratio -1.71
EV/EBITDA 18.25 Dividend Yield 0.00%
Market Cap 10.40B Enterprise Value 9.73B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 3.22B 2.85B 2.42B 2.10B 1.85B
Net Income 348.90M 426.86M 167.65M 141.56M -64.08M
EPS (Diluted) 1.80 2.21 0.88 0.75 -0.35
Gross Profit 2.48B 2.27B 1.89B 1.59B 1.38B
Operating Income 533.48M 484.21M 185.77M 160.97M -82.34M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 7.59B 6.99B 6.84B 6.38B 6.00B
Total Liabilities 1.51B 1.33B 1.89B 1.77B 1.74B
Shareholders' Equity 6.09B 5.66B 4.95B 4.60B 4.27B
Total Debt 642.87M 649.47M 1.10B 1.09B 1.09B
Cash & Equivalents 1.31B 942.84M 755.13M 724.53M 587.28M
Current Assets 3.95B 3.23B 2.96B 2.75B 2.27B
Current Liabilities 759.03M 606.99M 1.18B 588.88M 546.50M

درجات الاستراتيجيات

This stock passed the criteria for 1 strategy

Score = fit strength (0–100)
Rank = position among all matches
#698 of 1052
37

النشاط الأخير

دخل Cash Flow Compounder
Mar 24, 2026